Clinical Trials - October 6, 2020
Immunicum announces next safety and enrollment update for Phase Ib/II trial
Immunicum has announced that a total of 15 patients have now been enrolled in the ongoing Phase Ib/II ILIAD combination trial. In addition, ilixadencel has maintained a consistent safety profile in the study to-date and the Dose Escalation Committee (DEC) confirmed there were no dose limiting toxicities. The Phase Ib portion of the ILIAD trial […]
Biotech Business - October 1, 2020
Immunicum announces update on corporate and clinical development strategy
Immunicum has announced an update on its corporate and clinical development strategy. “With the information presented today at the corporate update event, we aim to provide an overview of our position as a cell therapy company, discuss strategic opportunities we intend to leverage and confirm our long-term mission for Immunicum,” commented Sven Rohmann, CEO of […]
In a new job - August 28, 2020
He is the new Chief Executive Officer of Immunicum
Immunicum has announced that Sven Rohmann has been appointed Chief Executive Officer (CEO) effective immediately. Bringing 30 years of industry experience from biotechnology and pharmaceutical companies as well as life science investment and company sale and acquisition experience, Rohmann will be leading Immunicum as it continues to develop ilixadencel, the company’s cell-based, off-the-shelf immune primer, […]
Clinical Trials - August 18, 2020
Immunicum updates survival data from Phase II trial
Immunicum has announced an update on survival data from the randomized Phase II MERECA trial evaluating its off-the-shelf immune primer, ilixadencel, in combination with SutentÒ (sunitinib) first-line treatment regimen in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). During the trial, 88 patients were randomly assigned in a two-to-one ratio to the ilixadencel combination […]
In a new job - December 13, 2019
Carlos de Sousa resigns as CEO of Immunicum
The Board of Directors of Immunicum has announced that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately. The Board has appointed Alex Karlsson-Parra, Immunicum’s Chief Scientific Officer, as acting CEO. The Board will begin recruitment of a new CEO shortly. “We thank Carlos for his efforts that have put […]
Clinical Trials - October 23, 2019
Immunicum announces positive preclinical data on Ilixadencel in combination with CTLA-4
The company has announced results from a preclinical study examining ilixadencel, an off-the-shelf, cell-based immune primer, tested in combination with the immune checkpoint inhibitor CTLA-4. As Immunicum continues to advance ilixadencel in clinical trials, these preclinical studies allow the company to identify potential synergistic combinations for ilixadencel in addition to gaining a stronger understanding of […]
